Fred Hutchinson Cancer Center: Leukemia trials

The registry lists 140 Leukemia studies with Fred Hutchinson Cancer Center as lead sponsor. 1 are open to participants now and 67 have results posted.

Phase 1 52Phase 2 104Phase 3 4No phase 17(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00096096Phase 2
• Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi AnemiaCompletedNCT00093743Phase 1
• Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic SyndromesCompletedNCT00093366Phase 1/2
• Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00089050Phase 2
• Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00089037Phase 1/2
• Study of the Emotional Needs of Caregivers of Stem Cell Transplantation PatientsCompletedNCT00082654Not applicable
• Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
• Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00062140Phase 1
• Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative DisorderCompletedNCT00054340Phase 1/2
• Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell TransplantTerminatedNCT00052598Phase 1/2
• Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell TransplantationCompletedNCT00052520Phase 1/2
• Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative DisorderCompletedNCT00049634Phase 1/2
• Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00027924Phase 2
• Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00027820Phase 1/2
• Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic LeukemiaCompletedNCT00027547Phase 1/2
• Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>CompletedNCT00025545Phase 2
• Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesCompletedNCT00014235Not applicable
• Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or ColonCompletedNCT00010283Phase 1/2
• Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00008151Phase 2
• Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic CancerCompletedNCT00006251Phase 1/2
• Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00005948Phase 2
• Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First RemissionCompletedNCT00005940Phase 2
• Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00005854Phase 2
• Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00005804Phase 2
• Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic LeukemiaCompletedNCT00005802Phase 1/2
• Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00005799Not applicable
• Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic DiseaseCompletedNCT00003913Phase 2
• Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell TransplantationCompletedNCT00003887Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Lymphoma or LeukemiaCompletedNCT00003874Phase 1/2
• Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic LeukemiaCompletedNCT00003870Phase 2
• Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid LeukemiaCompletedNCT00003868Phase 2
• Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple MyelomaCompletedNCT00003196Not applicable
• Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid LeukemiaCompletedNCT00003145Phase 2
• Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow TransplantWithdrawnNCT00002790Phase 1/2
• Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid LeukemiaCompletedNCT00002789Phase 3
• High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00002788Phase 1
• Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00002674Phase 2
• Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First RelapseCompletedNCT00002554Phase 2
• Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic CancerCompletedNCT00002553Phase 2
• Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow TransplantationCompletedNCT00002456Phase 3